TW202005651A - 波齊替尼(poziotinib)與抗her1、her2或her4抗體之組合及使用彼之方法 - Google Patents
波齊替尼(poziotinib)與抗her1、her2或her4抗體之組合及使用彼之方法 Download PDFInfo
- Publication number
- TW202005651A TW202005651A TW108122227A TW108122227A TW202005651A TW 202005651 A TW202005651 A TW 202005651A TW 108122227 A TW108122227 A TW 108122227A TW 108122227 A TW108122227 A TW 108122227A TW 202005651 A TW202005651 A TW 202005651A
- Authority
- TW
- Taiwan
- Prior art keywords
- her2
- cancer
- bozitinib
- breast cancer
- her1
- Prior art date
Links
- LPFWVDIFUFFKJU-UHFFFAOYSA-N 1-[4-[4-(3,4-dichloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]prop-2-en-1-one Chemical compound C=12C=C(OC3CCN(CC3)C(=O)C=C)C(OC)=CC2=NC=NC=1NC1=CC=C(Cl)C(Cl)=C1F LPFWVDIFUFFKJU-UHFFFAOYSA-N 0.000 title claims abstract description 4
- 229950009876 poziotinib Drugs 0.000 title claims abstract description 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 title claims description 121
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 title claims description 121
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 title claims description 34
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 title claims description 33
- 238000000034 method Methods 0.000 title description 39
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 64
- 201000011510 cancer Diseases 0.000 claims abstract description 42
- QHXLXUIZUCJRKV-UHFFFAOYSA-N 6-(1-cyclopropylpyrazol-4-yl)-3-[difluoro-(6-fluoro-2-methylindazol-5-yl)methyl]-[1,2,4]triazolo[4,3-b]pyridazine Chemical compound FC1=CC2=NN(C)C=C2C=C1C(F)(F)C(N1N=2)=NN=C1C=CC=2C(=C1)C=NN1C1CC1 QHXLXUIZUCJRKV-UHFFFAOYSA-N 0.000 claims description 110
- 238000011282 treatment Methods 0.000 claims description 61
- 229960001612 trastuzumab emtansine Drugs 0.000 claims description 59
- 229960000575 trastuzumab Drugs 0.000 claims description 58
- 239000003814 drug Substances 0.000 claims description 50
- 102000001301 EGF receptor Human genes 0.000 claims description 49
- 206010006187 Breast cancer Diseases 0.000 claims description 48
- 208000026310 Breast neoplasm Diseases 0.000 claims description 47
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 45
- 206010017758 gastric cancer Diseases 0.000 claims description 45
- 201000011549 stomach cancer Diseases 0.000 claims description 45
- 229930012538 Paclitaxel Natural products 0.000 claims description 37
- 229960001592 paclitaxel Drugs 0.000 claims description 37
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 37
- 229940079593 drug Drugs 0.000 claims description 34
- 230000002018 overexpression Effects 0.000 claims description 34
- 238000001990 intravenous administration Methods 0.000 claims description 33
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 claims description 32
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 claims description 32
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 claims description 32
- 230000003321 amplification Effects 0.000 claims description 27
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 27
- 238000001802 infusion Methods 0.000 claims description 25
- 238000003364 immunohistochemistry Methods 0.000 claims description 23
- 230000002411 adverse Effects 0.000 claims description 15
- 229960002066 vinorelbine Drugs 0.000 claims description 15
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 14
- 239000000427 antigen Substances 0.000 claims description 14
- 102000036639 antigens Human genes 0.000 claims description 14
- 108091007433 antigens Proteins 0.000 claims description 14
- 229960005395 cetuximab Drugs 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 13
- 229960002949 fluorouracil Drugs 0.000 claims description 13
- 206010012735 Diarrhoea Diseases 0.000 claims description 11
- 230000027455 binding Effects 0.000 claims description 11
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 11
- 229960004316 cisplatin Drugs 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 238000002509 fluorescent in situ hybridization Methods 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 9
- 206010055113 Breast cancer metastatic Diseases 0.000 claims description 8
- 208000010201 Exanthema Diseases 0.000 claims description 8
- 201000005884 exanthem Diseases 0.000 claims description 8
- 231100000226 haematotoxicity Toxicity 0.000 claims description 8
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 8
- 206010037844 rash Diseases 0.000 claims description 8
- 230000001394 metastastic effect Effects 0.000 claims description 7
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 7
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 7
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 7
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 6
- 101150054472 HER2 gene Proteins 0.000 claims description 6
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 108700020302 erbB-2 Genes Proteins 0.000 claims description 6
- 201000004101 esophageal cancer Diseases 0.000 claims description 6
- 102000015694 estrogen receptors Human genes 0.000 claims description 6
- 108010038795 estrogen receptors Proteins 0.000 claims description 6
- 238000011156 evaluation Methods 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- 206010048610 Cardiotoxicity Diseases 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 206010014418 Electrolyte imbalance Diseases 0.000 claims description 5
- 206010028116 Mucosal inflammation Diseases 0.000 claims description 5
- 201000010927 Mucositis Diseases 0.000 claims description 5
- 231100000259 cardiotoxicity Toxicity 0.000 claims description 5
- 231100000304 hepatotoxicity Toxicity 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 206010016256 fatigue Diseases 0.000 claims description 4
- 230000007056 liver toxicity Effects 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 3
- 238000009104 chemotherapy regimen Methods 0.000 claims description 2
- 229940011871 estrogen Drugs 0.000 claims description 2
- 239000000262 estrogen Substances 0.000 claims description 2
- 201000007280 estrogen-receptor negative breast cancer Diseases 0.000 claims description 2
- 208000026037 malignant tumor of neck Diseases 0.000 claims description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims 2
- 238000001647 drug administration Methods 0.000 claims 1
- 229960003387 progesterone Drugs 0.000 claims 1
- 239000000186 progesterone Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 23
- 108060006698 EGF receptor Proteins 0.000 description 17
- 230000004044 response Effects 0.000 description 17
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 16
- 239000002246 antineoplastic agent Substances 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 230000035772 mutation Effects 0.000 description 14
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 13
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 description 12
- 208000004235 neutropenia Diseases 0.000 description 11
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 11
- -1 EC-1069 Chemical compound 0.000 description 10
- 231100000682 maximum tolerated dose Toxicity 0.000 description 10
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 10
- 230000002195 synergetic effect Effects 0.000 description 10
- 230000008685 targeting Effects 0.000 description 10
- 230000001988 toxicity Effects 0.000 description 10
- 231100000419 toxicity Toxicity 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 9
- 229960002930 sirolimus Drugs 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 230000000903 blocking effect Effects 0.000 description 7
- 239000000562 conjugate Substances 0.000 description 7
- 206010066896 HER-2 positive gastric cancer Diseases 0.000 description 6
- 229940127089 cytotoxic agent Drugs 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 208000002633 Febrile Neutropenia Diseases 0.000 description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000000611 antibody drug conjugate Substances 0.000 description 5
- 229940049595 antibody-drug conjugate Drugs 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 201000005202 lung cancer Diseases 0.000 description 5
- 208000020816 lung neoplasm Diseases 0.000 description 5
- 229910052697 platinum Inorganic materials 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000009097 single-agent therapy Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 4
- 229940123237 Taxane Drugs 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 229940041181 antineoplastic drug Drugs 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000007681 cardiovascular toxicity Effects 0.000 description 4
- 229960003668 docetaxel Drugs 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 201000010536 head and neck cancer Diseases 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010043554 thrombocytopenia Diseases 0.000 description 4
- WAVYAFBQOXCGSZ-UHFFFAOYSA-N 2-fluoropyrimidine Chemical compound FC1=NC=CC=N1 WAVYAFBQOXCGSZ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 229940122803 Vinca alkaloid Drugs 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 229960005558 mertansine Drugs 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229960002087 pertuzumab Drugs 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 208000003265 stomatitis Diseases 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- YYSFXUWWPNHNAZ-PKJQJFMNSA-N umirolimus Chemical compound C1[C@@H](OC)[C@H](OCCOCC)CC[C@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 YYSFXUWWPNHNAZ-PKJQJFMNSA-N 0.000 description 3
- 229960004528 vincristine Drugs 0.000 description 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 3
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 3
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- JXONINOYTKKXQQ-CQSZACIVSA-N Crolibulin Chemical compound BrC1=C(OC)C(OC)=CC([C@@H]2C3=CC=C(N)C(N)=C3OC(N)=C2C#N)=C1 JXONINOYTKKXQQ-CQSZACIVSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- XOZIUKBZLSUILX-SDMHVBBESA-N Epothilone D Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C(/C)=C/C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C XOZIUKBZLSUILX-SDMHVBBESA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 238000011460 HER2-targeted therapy Methods 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 229940121849 Mitotic inhibitor Drugs 0.000 description 2
- 102000038030 PI3Ks Human genes 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 2
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000013394 Troponin I Human genes 0.000 description 2
- 108010065729 Troponin I Proteins 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 231100000060 cardiovascular toxicity Toxicity 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 231100001159 controllable toxicity Toxicity 0.000 description 2
- 229950005509 crolibulin Drugs 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- XOZIUKBZLSUILX-UHFFFAOYSA-N desoxyepothilone B Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC(C)=CCC1C(C)=CC1=CSC(C)=N1 XOZIUKBZLSUILX-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- XOPYFXBZMVTEJF-PDACKIITSA-N eleutherobin Chemical compound C(/[C@H]1[C@H](C(=CC[C@@H]1C(C)C)C)C[C@@H]([C@@]1(C)O[C@@]2(C=C1)OC)OC(=O)\C=C\C=1N=CN(C)C=1)=C2\CO[C@@H]1OC[C@@H](O)[C@@H](O)[C@@H]1OC(C)=O XOPYFXBZMVTEJF-PDACKIITSA-N 0.000 description 2
- XOPYFXBZMVTEJF-UHFFFAOYSA-N eleutherobin Natural products C1=CC2(OC)OC1(C)C(OC(=O)C=CC=1N=CN(C)C=1)CC(C(=CCC1C(C)C)C)C1C=C2COC1OCC(O)C(O)C1OC(C)=O XOPYFXBZMVTEJF-UHFFFAOYSA-N 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 2
- XOZIUKBZLSUILX-GIQCAXHBSA-N epothilone D Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 XOZIUKBZLSUILX-GIQCAXHBSA-N 0.000 description 2
- 229960001433 erlotinib Drugs 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 238000003205 genotyping method Methods 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 229940124302 mTOR inhibitor Drugs 0.000 description 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 2
- 229960000901 mepacrine Drugs 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- ANZJBCHSOXCCRQ-FKUXLPTCSA-N mertansine Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCS)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ANZJBCHSOXCCRQ-FKUXLPTCSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000009117 preventive therapy Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 102200048955 rs121434569 Human genes 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 229940126586 small molecule drug Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- 229960004355 vindesine Drugs 0.000 description 2
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 2
- AADVCYNFEREWOS-UHFFFAOYSA-N (+)-DDM Natural products C=CC=CC(C)C(OC(N)=O)C(C)C(O)C(C)CC(C)=CC(C)C(O)C(C)C=CC(O)CC1OC(=O)C(C)C(O)C1C AADVCYNFEREWOS-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- YOVVNQKCSKSHKT-HNNXBMFYSA-N (2s)-1-[4-[[2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]piperazin-1-yl]-2-hydroxypropan-1-one Chemical compound C1CN(C(=O)[C@@H](O)C)CCN1CC1=C(C)C2=NC(C=3C=NC(N)=NC=3)=NC(N3CCOCC3)=C2S1 YOVVNQKCSKSHKT-HNNXBMFYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- SOJJMSYMCLIQCZ-CYBMUJFWSA-N 1-[(2r)-4-[2-(2-aminopyrimidin-5-yl)-6-morpholin-4-yl-9-(2,2,2-trifluoroethyl)purin-8-yl]-2-methylpiperazin-1-yl]ethanone Chemical compound C1CN(C(C)=O)[C@H](C)CN1C1=NC2=C(N3CCOCC3)N=C(C=3C=NC(N)=NC=3)N=C2N1CC(F)(F)F SOJJMSYMCLIQCZ-CYBMUJFWSA-N 0.000 description 1
- DWZAEMINVBZMHQ-UHFFFAOYSA-N 1-[4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl]-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea Chemical compound C1CC(N(C)C)CCN1C(=O)C(C=C1)=CC=C1NC(=O)NC1=CC=C(C=2N=C(N=C(N=2)N2CCOCC2)N2CCOCC2)C=C1 DWZAEMINVBZMHQ-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- FIDMEHCRMLKKPZ-YSMBQZINSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;[2-methoxy-5-[(z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl] dihydrogen phosphate Chemical compound OCC(N)(CO)CO.C1=C(OP(O)(O)=O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 FIDMEHCRMLKKPZ-YSMBQZINSA-N 0.000 description 1
- RGHYDLZMTYDBDT-UHFFFAOYSA-N 2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)-7-pyrido[2,3-d]pyrimidinone Chemical compound O=C1N(CC)C2=NC(N)=NC(C)=C2C=C1C=1C=CNN=1 RGHYDLZMTYDBDT-UHFFFAOYSA-N 0.000 description 1
- DPEXZURXDJIYRS-UHFFFAOYSA-N 2-amino-n-[2-methoxy-5-[5-(3,4,5-trimethoxyphenyl)-1,2-oxazol-4-yl]phenyl]-3-phenylpropanamide;hydrochloride Chemical compound Cl.COC1=CC=C(C2=C(ON=C2)C=2C=C(OC)C(OC)=C(OC)C=2)C=C1NC(=O)C(N)CC1=CC=CC=C1 DPEXZURXDJIYRS-UHFFFAOYSA-N 0.000 description 1
- XDZMPRGFOOFSBL-UHFFFAOYSA-N 2-ethoxybenzoic acid Chemical compound CCOC1=CC=CC=C1C(O)=O XDZMPRGFOOFSBL-UHFFFAOYSA-N 0.000 description 1
- AFDSETGKYZMEEA-HZJYTTRNSA-N 2-hydroxylinoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCC(O)C(O)=O AFDSETGKYZMEEA-HZJYTTRNSA-N 0.000 description 1
- CQOQDQWUFQDJMK-SSTWWWIQSA-N 2-methoxy-17beta-estradiol Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CCC1=C2C=C(OC)C(O)=C1 CQOQDQWUFQDJMK-SSTWWWIQSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- JUSFANSTBFGBAF-IRXDYDNUSA-N 3-[2,4-bis[(3s)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC(C=2N=C3N=C(N=C(C3=CC=2)N2[C@H](COCC2)C)N2[C@H](COCC2)C)=C1 JUSFANSTBFGBAF-IRXDYDNUSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- FPEIJQLXFHKLJV-UHFFFAOYSA-N 4-[6-(1h-indol-5-yl)-1-[1-(pyridin-3-ylmethyl)piperidin-4-yl]pyrazolo[3,4-d]pyrimidin-4-yl]morpholine Chemical compound C=1C=CN=CC=1CN(CC1)CCC1N(C1=NC(=N2)C=3C=C4C=CNC4=CC=3)N=CC1=C2N1CCOCC1 FPEIJQLXFHKLJV-UHFFFAOYSA-N 0.000 description 1
- IMXHGCRIEAKIBU-UHFFFAOYSA-N 4-[6-[4-(methoxycarbonylamino)phenyl]-4-(4-morpholinyl)-1-pyrazolo[3,4-d]pyrimidinyl]-1-piperidinecarboxylic acid methyl ester Chemical compound C1=CC(NC(=O)OC)=CC=C1C1=NC(N2CCOCC2)=C(C=NN2C3CCN(CC3)C(=O)OC)C2=N1 IMXHGCRIEAKIBU-UHFFFAOYSA-N 0.000 description 1
- ADGGYDAFIHSYFI-UHFFFAOYSA-N 5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=NC(N2CCOCC2)=NC(N2CCOCC2)=N1 ADGGYDAFIHSYFI-UHFFFAOYSA-N 0.000 description 1
- GYLDXIAOMVERTK-UHFFFAOYSA-N 5-(4-amino-1-propan-2-yl-3-pyrazolo[3,4-d]pyrimidinyl)-1,3-benzoxazol-2-amine Chemical compound C12=C(N)N=CN=C2N(C(C)C)N=C1C1=CC=C(OC(N)=N2)C2=C1 GYLDXIAOMVERTK-UHFFFAOYSA-N 0.000 description 1
- LGWACEZVCMBSKW-UHFFFAOYSA-N 5-(6,6-dimethyl-4-morpholin-4-yl-8,9-dihydropurino[8,9-c][1,4]oxazin-2-yl)pyrimidin-2-amine Chemical compound CC1(C)OCCN(C2=N3)C1=NC2=C(N1CCOCC1)N=C3C1=CN=C(N)N=C1 LGWACEZVCMBSKW-UHFFFAOYSA-N 0.000 description 1
- XOZLHJMDLKDZAL-UHFFFAOYSA-N 5-[6-(3-methoxyoxetan-3-yl)-7-methyl-4-morpholin-4-ylthieno[3,2-d]pyrimidin-2-yl]pyrimidin-2-amine Chemical compound S1C2=C(N3CCOCC3)N=C(C=3C=NC(N)=NC=3)N=C2C(C)=C1C1(OC)COC1 XOZLHJMDLKDZAL-UHFFFAOYSA-N 0.000 description 1
- ACCFLVVUVBJNGT-AWEZNQCLSA-N 8-[5-(2-hydroxypropan-2-yl)pyridin-3-yl]-1-[(2s)-2-methoxypropyl]-3-methylimidazo[4,5-c]quinolin-2-one Chemical compound CN1C(=O)N(C[C@H](C)OC)C(C2=C3)=C1C=NC2=CC=C3C1=CN=CC(C(C)(C)O)=C1 ACCFLVVUVBJNGT-AWEZNQCLSA-N 0.000 description 1
- 229940125664 ABTL0812 Drugs 0.000 description 1
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 1
- 206010001150 Adenocarcinoma gastric Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 101100450694 Arabidopsis thaliana HFR1 gene Proteins 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- UFKLYTOEMRFKAD-SHTZXODSSA-N C1C[C@@H](OC)CC[C@@H]1N1C2=NC(C=3C=NC(=CC=3)C(C)(C)O)=CN=C2NCC1=O Chemical compound C1C[C@@H](OC)CC[C@@H]1N1C2=NC(C=3C=NC(=CC=3)C(C)(C)O)=CN=C2NCC1=O UFKLYTOEMRFKAD-SHTZXODSSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- AADVCYNFEREWOS-OBRABYBLSA-N Discodermolide Chemical compound C=C\C=C/[C@H](C)[C@H](OC(N)=O)[C@@H](C)[C@H](O)[C@@H](C)C\C(C)=C/[C@H](C)[C@@H](O)[C@@H](C)\C=C/[C@@H](O)C[C@@H]1OC(=O)[C@H](C)[C@@H](O)[C@H]1C AADVCYNFEREWOS-OBRABYBLSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000015617 Janus Kinases Human genes 0.000 description 1
- 108010024121 Janus Kinases Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 229930126263 Maytansine Natural products 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 229940122255 Microtubule inhibitor Drugs 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000187391 Streptomyces hygroscopicus Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000005497 Thymidylate Synthase Human genes 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- XJXKGUZINMNEDK-GPJOBVNKSA-L [(4r,5r)-5-(aminomethyl)-2-propan-2-yl-1,3-dioxolan-4-yl]methanamine;platinum(2+);propanedioate Chemical compound [Pt+2].[O-]C(=O)CC([O-])=O.CC(C)C1O[C@H](CN)[C@@H](CN)O1 XJXKGUZINMNEDK-GPJOBVNKSA-L 0.000 description 1
- XSMVECZRZBFTIZ-UHFFFAOYSA-M [2-(aminomethyl)cyclobutyl]methanamine;2-oxidopropanoate;platinum(4+) Chemical compound [Pt+4].CC([O-])C([O-])=O.NCC1CCC1CN XSMVECZRZBFTIZ-UHFFFAOYSA-M 0.000 description 1
- VJLRLTSXTLICIR-UHFFFAOYSA-N [8-[6-amino-5-(trifluoromethyl)pyridin-3-yl]-1-[6-(2-cyanopropan-2-yl)pyridin-3-yl]-3-methylimidazo[4,5-c]quinolin-2-ylidene]cyanamide Chemical compound N#CN=C1N(C)C2=CN=C3C=CC(C=4C=C(C(N)=NC=4)C(F)(F)F)=CC3=C2N1C1=CC=C(C(C)(C)C#N)N=C1 VJLRLTSXTLICIR-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940064305 adrucil Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 description 1
- 229960001573 cabazitaxel Drugs 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000023402 cell communication Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- XDLYKKIQACFMJG-WKILWMFISA-N chembl1234354 Chemical compound C1=NC(OC)=CC=C1C(C1=O)=CC2=C(C)N=C(N)N=C2N1[C@@H]1CC[C@@H](OCCO)CC1 XDLYKKIQACFMJG-WKILWMFISA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- LRCTTYSATZVTRI-UHFFFAOYSA-L cyclohexane-1,2-diamine;platinum(4+);tetradecanoate Chemical compound [Pt+4].NC1CCCCC1N.CCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCC([O-])=O LRCTTYSATZVTRI-UHFFFAOYSA-L 0.000 description 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- LVXJQMNHJWSHET-AATRIKPKSA-N dacomitinib Chemical compound C=12C=C(NC(=O)\C=C\CN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 LVXJQMNHJWSHET-AATRIKPKSA-N 0.000 description 1
- 229950002205 dacomitinib Drugs 0.000 description 1
- 229950006418 dactolisib Drugs 0.000 description 1
- JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- VFNGKCDDZUSWLR-UHFFFAOYSA-N disulfuric acid Chemical compound OS(=O)(=O)OS(O)(=O)=O VFNGKCDDZUSWLR-UHFFFAOYSA-N 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- QXRSDHAAWVKZLJ-TYFQHMATSA-N epothilone b Chemical compound C/C([C@@H]1C[C@@H]2O[C@@]2(C)CCC[C@@H]([C@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-TYFQHMATSA-N 0.000 description 1
- 229950006835 eptaplatin Drugs 0.000 description 1
- 229940082789 erbitux Drugs 0.000 description 1
- QAMYWGZHLCQOOJ-PWIVHLLHSA-N eribulin mesylate Chemical compound CS(O)(=O)=O.C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 QAMYWGZHLCQOOJ-PWIVHLLHSA-N 0.000 description 1
- 229960000439 eribulin mesylate Drugs 0.000 description 1
- 210000003236 esophagogastric junction Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960001766 estramustine phosphate sodium Drugs 0.000 description 1
- IIUMCNJTGSMNRO-VVSKJQCTSA-L estramustine sodium phosphate Chemical compound [Na+].[Na+].ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 IIUMCNJTGSMNRO-VVSKJQCTSA-L 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000011354 first-line chemotherapy Methods 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 229950008991 lobaplatin Drugs 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical class CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- VDOCQQKGPJENHJ-UHFFFAOYSA-N methyl n-[4-[4-morpholin-4-yl-1-[1-(pyridin-3-ylmethyl)piperidin-4-yl]pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]carbamate Chemical compound C1=CC(NC(=O)OC)=CC=C1C1=NC(N2CCOCC2)=C(C=NN2C3CCN(CC=4C=NC=CC=4)CC3)C2=N1 VDOCQQKGPJENHJ-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 231100000782 microtubule inhibitor Toxicity 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229950004962 miriplatin Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- OCKHRKSTDPOHEN-BQYQJAHWSA-N n-(4-methoxyphenyl)sulfonyl-n-[2-[(e)-2-(1-oxidopyridin-1-ium-4-yl)ethenyl]phenyl]acetamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(C)=O)C1=CC=CC=C1\C=C\C1=CC=[N+]([O-])C=C1 OCKHRKSTDPOHEN-BQYQJAHWSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- GDCJHDUWWAKBIW-UHFFFAOYSA-N n-[4-[4-[2-(difluoromethyl)-4-methoxybenzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl]-2-(dimethylamino)ethanesulfonamide Chemical compound FC(F)C1=NC=2C(OC)=CC=CC=2N1C(N=1)=NC(N2CCOCC2)=NC=1C1=CC=C(NS(=O)(=O)CCN(C)C)C=C1 GDCJHDUWWAKBIW-UHFFFAOYSA-N 0.000 description 1
- 239000002159 nanocrystal Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229940086322 navelbine Drugs 0.000 description 1
- 229950007221 nedaplatin Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 229950007460 patupilone Drugs 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229950005566 picoplatin Drugs 0.000 description 1
- IIMIOEBMYPRQGU-UHFFFAOYSA-L picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 102220004843 rs397516975 Human genes 0.000 description 1
- 102220014234 rs397516981 Human genes 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000009118 salvage therapy Methods 0.000 description 1
- 229950009216 sapanisertib Drugs 0.000 description 1
- 229960005399 satraplatin Drugs 0.000 description 1
- 190014017285 satraplatin Chemical compound 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000007761 synergistic anti-cancer Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- MODVSQKJJIBWPZ-VLLPJHQWSA-N tesetaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3CC[C@@]2(C)[C@H]2[C@@H](C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C(=CC=CN=4)F)C[C@]1(O)C3(C)C)O[C@H](O2)CN(C)C)C(=O)C1=CC=CC=C1 MODVSQKJJIBWPZ-VLLPJHQWSA-N 0.000 description 1
- 229940100611 topical cream Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 229950007775 umirolimus Drugs 0.000 description 1
- 231100000402 unacceptable toxicity Toxicity 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 229960000922 vinflunine Drugs 0.000 description 1
- NMDYYWFGPIMTKO-HBVLKOHWSA-N vinflunine Chemical compound C([C@@](C1=C(C2=CC=CC=C2N1)C1)(C2=C(OC)C=C3N(C)[C@@H]4[C@@]5(C3=C2)CCN2CC=C[C@]([C@@H]52)([C@H]([C@]4(O)C(=O)OC)OC(C)=O)CC)C(=O)OC)[C@H]2C[C@@H](C(C)(F)F)CN1C2 NMDYYWFGPIMTKO-HBVLKOHWSA-N 0.000 description 1
- CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 1
- 229960002360 vintafolide Drugs 0.000 description 1
- KUZYSQSABONDME-QRLOMCMNSA-N vintafolide Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)NNC(=O)OCCSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)CC[C@H](NC(=O)C=4C=CC(NCC=5N=C6C(=O)NC(N)=NC6=NC=5)=CC=4)C(O)=O)C(O)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KUZYSQSABONDME-QRLOMCMNSA-N 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 229950009819 zotarolimus Drugs 0.000 description 1
- CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/5545—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having eight-membered rings not containing additional condensed or non-condensed nitrogen-containing 3-7 membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Abstract
本發明提供波齊替尼(poziotinib)與抗HER1、抗HER2或抗HER4抗體、視需要與其他藥劑之組合,及該等組合於治療癌症之用途。
Description
本發明大體上關於一種藉由向個體投與醫藥組合物來治療癌症之方法,該醫藥組合物包含波齊替尼與抗HER1、HER2或HER4抗體之組合,視需要另外與額外抗癌藥物之組合。
已知表皮生長因子受體(EGFR)家族具有四個成員,即HER1/ErbB1(通常稱為「EGFR」)、HER2/ErbB2、HER3/ErbB3及HER4/ErbB4。EGFR通過細胞內訊號轉導在正常細胞調節中發揮重要作用,且此等蛋白質調節細胞生長、凋亡、遷移、黏附及分化。EGFR在大多數實體腫瘤細胞中異常過度表現或突變,且此等受體之過度活化觸發相互關聯之傳訊路徑之複雜多層網路,包括有絲分裂原活化蛋白激酶(MAPK)、磷酸肌醇-3-激酶/AKT (PI3K/AKT)及詹納斯激酶/訊號轉導因子及轉錄激活因子(JAK/STAT)路徑之下游上調促進癌症生長、分化、血管生成、轉移及抗性。例如,HER2在約20%至25%之乳癌中過度表現,且為預後標誌物。HER2陽性乳癌之特徵在於比HER2陰性亞型更具臨床攻擊性及侵襲性,與增加之生長速度相關聯、早期全身轉移及預後不良。因此,阻斷由表皮生長因子受體介導之腫瘤細胞傳訊路徑為潛在地產生抗腫瘤效果之理想靶標。
靶向EGFR之抗癌藥物分為兩組:靶向細胞外結構域之單株抗體及靶向細胞內酪胺酸激酶之小分子藥物。由於與表皮生長因子受體之選擇性結合,單株抗體具有良好之藥效及較低副作用之優點。然而,單株抗體之缺點在於其等昂貴且必須藉由注射投與。同時,靶向酪胺酸激酶之小分子藥物相對廉價且可口服投與,且其等亦通過選擇性地與受體亞型(例如EGFR、HER2、HER3或HER4)相互作用或同時與多種受體亞型相互作用而具有良好之藥效。
阿多曲妥珠單抗依坦辛(Ado-trastuzumab emtansine (T-DM1))係靶向HER2之抗體-藥物結合物之實例,其中該抗體係人類化抗HER2 IgG1,曲妥珠單抗經由穩定之硫醚連接子MCC (環己烷-1-甲酸4-[N-馬來醯亞胺基甲基]酯)與微管抑制藥物DM1 (美登素(maytansine)衍生物)共價連接。「依坦辛」係指MCC-DM1複合物。T-DM1被指示為用於治療先前已經單獨或組合地接受曲妥珠單抗及紫杉烷之罹患HER2陽性轉移性乳癌患者之單藥劑。曲妥珠單抗-DM1結合物(T-DM1)之結構式如下所示。
波齊替尼(HM781-36B)係美國專利8,188,102號中描述之新穎口服不可逆泛HER抑制劑,該案以全文引用併入本文中。波齊替尼係一種基於喹唑啉之酪胺酸酶激酶抑制劑(如下所示之結構),其不可逆地阻斷通過酪胺酸酶激酶受體(包括HER1 (EGFR)、HER2及HER4野生型受體)之EGFR家族,以及具有活化突變之受體之傳訊。此繼而導致抑制過度表現此等受體之腫瘤細胞之增殖。波齊替尼之投與可導致抑制過度表現此等受體之腫瘤細胞之增殖。波齊替尼之化學式為下文顯示之1-[4-[4-(3,4-二氯-2-氟苯基胺基)-7-甲氧基喹唑啉-6-基氧基]-哌啶-1-基]丙-2-烯-1-酮。
近年來,已報導EGFR靶向療法中之抗性表現會減少所用藥物之反應時間。已報導,用吉非替尼(gefitinib)或厄洛替尼(erlotinib)治療之罹患EGFR活化突變之非小細胞肺癌(NSCLC)患者在治療約8至16個月後對該藥物具有抗性,且觀測到約60%之患者由於EGFR T790M突變而具有抗性(Helena A.Yu等人,Clin. Cancer Res. 19(8), 2240, 2013)。此外,在用抗體藥物曲妥珠單抗治療之HER2陽性轉移性乳癌患者之情況中,已知66%至88%之患者由於各種機製而重新展現出抗性或獲得性抗性(Alice Chung等人,Clin. Breast Cancer 13(4), 223, 2013)。就此而言,靶向EGFR之治療劑之開發受到限制,因為其療效由於產生一級及二級抗性而無法長時間維持,儘管靶向EGFR之治療劑對具有HER2過度表現或突變之實體癌之治療具有可觀效果。
胃癌(GC)為全球第五大常見癌症且為癌症相關死亡之第三大原因。對於罹患轉移性或複發性GC之大多數患者,化療係治療之主要方法。儘管沒有普遍接受之化療方案,但最常用氟嘧啶及鉑試劑之組合。一些醫生在此雙重組合中加入多西紫杉醇(docetaxel)或表柔比星(epirubicin);然而,由於毒性問題,不常規使用三聯組合。
因此,迫切需要一種有效治療性治療,其可在治療具有EGFR過度表現或突變(特別是HER2)之實體癌方面增強療效並克服抗性。本發明解決此需求。
在一個態樣中,本發明提供治療個體之癌症之方法,該方法包括向個體投與治療有效量之波齊替尼及抗HER1、HER2或HER4抗體、其結合物或片段,其中該癌症係與HER1、HER2或HER4,或HER1、HER2或HER4之突變體之過度表現或擴增相關聯。適當地,抗HER2抗體係曲妥珠單抗或其藥物結合物諸如曲妥珠單抗依坦辛(T-DM1)。該方法可另外包括投與至少一種選自由紫杉醇(paclitaxel)、順鉑、5-氟尿嘧啶、長春瑞濱(vinorelbine)、西妥昔單抗(cetuximab)及其任何組合組成之群之藥劑。該方法適用於選自非小細胞肺癌、乳癌、胃癌、結腸癌、胰臟癌、前列腺癌、骨髓瘤、頭頸癌、卵巢癌、食道癌及轉移性細胞癌之癌症。此類癌症可為原發性或繼發性。適當地,治療癌症之方法係針對罹患乳癌或肺癌或胃癌之個體。適當地,乳癌係包括轉移性乳癌之乳癌。適當地,治療癌症之方法係針對罹患胃癌(較佳HER2陽性胃癌,更佳先前已用一種或多種化療劑治療之HER2陽性胃癌)之個體。
另一態樣中,本發明提供治療有此需要之個體之乳癌之方法,其中該乳癌係與HER1、HER2、HER4,或HER2之突變體之過度表現或擴增相關聯,其中該方法包括以下步驟:a)在21天週期±3天中,i)投與單一標準劑量之抗HER2抗體或其結合物諸如T-DM1;及ii)投與每日劑量之波齊替尼;及b)視需要重複該週期。適當地,T-DM1係藉由靜脈內(IV)輸注投與。適當地,T-DM1標準劑量為0.5至10 mg/kg。適當地,T-DM1係以3.6 mg/kg投與。適當地,波齊替尼係口服投與。適當地,波齊替尼之口服劑量係選自0.5至50 mg/天。
在另一態樣中,本發明提供改善正在經歷與HER2或HER2突變體之過度表現或擴增相關聯之乳癌治療之個體中之不良事件概況之方法,該方法包括以下步驟:a)在21天週期±3天中,i)投與單一標準劑量之T-DM1;及ii)投與每日劑量之波齊替尼;及b)視需要重複該週期。
本發明之另一態樣提供用於治療個體之癌症之組合,其中該癌症係與HER1、HER2或HER4,或HER1、HER2或HER4之突變體之過度表現或擴增相關聯,且其中該組合包含治療有效量之波齊替尼及T-DM1,其中波齊替尼係口服投與及T-DM1係藉由IV輸注投與。
一般技術者閱讀以下詳細描述將明白其他態樣及優點。雖然治療癌症之方法及醫藥組合易於具有各種形式之實施方案,但是下文之描述包括具體實施例,應理解此等實施例為說明性,且無意將本發明限制於本文所述之具體實施例。
相關申請案之交叉參考
本申請案主張2019年3月1日申請之美國臨時申請案第62/812,656號及2018年6月25日申請之美國臨時申請案第62/689,282號之權益,該等案件之整個揭示內容以引用之方式併入本文中。
定義
如本文所揭示,提供許多值範圍。應理解,除非上下文另有明確規定,否則亦明確揭示在該範圍之上限及下限之間之各介入值,精確至下限單位之十分之一。在所述範圍內之任何規定值或介入值與所述範圍內之任何其他規定或介入值之間之各較小範圍均包涵在本發明內。此等較小範圍之上限及下限可獨立地包括在該範圍內或不包括在該範圍內,且其中任一個限值、無一個限值或兩個限值包括在較小範圍中之各範圍亦包涵在本發明內,受制於規定範圍內之任何明確排除之限值。在規定範圍包括一個或兩個限值之情況下,排除彼等包括之限值之任一者或兩者之範圍亦包括在本發明中。
如本文所用,術語「約」一般係指加上或減去所示數字之10%。例如,「約10%」可表示9%至11%之範圍,「約20」可表示18至22之範圍。「約」之其他含義可從上下文中顯而易見,諸如四捨五入,因此例如,「約1」亦可意謂0.5至1.4。如本文所用,術語「及/或」包括相關所列項之一者或多者之任何及所有組合。諸如「...中之至少一者」 (在要素清單之前時)之表述修飾整個要素清單而不修飾清單之個別要素。當提及給藥方案時,術語「天」、「每天」等係指在一個日曆天內之時間,其在午夜開始並在隨後之午夜結束。
本文所用之術語「治療」及其任何衍生詞意謂治療性療法。關於特定病症,治療意謂:(1)改善或預防病症之一種或多種生物學表現之狀況,(2)干擾(a)導致該病症或造成該病症之生物級聯中之一個或多個點或(b)該病症之一種或多種生物學表現,(3)減輕與其病症或治療相關聯之一種或多種症狀、效應或副作用,或(4)減緩病症之進展或病症之一種或多種生物學表現。由此亦預期預防性療法。技術人員將理解「預防」不為絕對術語。在醫學中,「預防」應理解為係指預防性投與藥物以實質性降低病症或其生物學表現之可能性或嚴重性,或延遲該病症或其生物學表現之發作。預防性療法係適當地用在例如當個體被視為具有發展癌症之高風險時,諸如當個體俱有強家族癌症史或個體已經暴露於致癌物時。
如本文所用,術語「有效量」意謂藥物或藥劑之量,其將引起例如由研究人員或臨床醫生尋求之組織、系統、動物或人類之生物學或醫學反應。此外,術語「治療有效量」意謂與未接受該量之相應個體相比導致疾病、病症或副作用之改進治療、癒合、預防或改善,或降低疾病或病症之發展速度之任何量。該術語在其範圍內亦包括有效增強正常生理功能之量。使用常規程序,一般技術者可容易地確定具體劑量。
本文所用之術語「組合」意謂治療有效量之組成藥物之同時投與或任何方式之單獨依序投與。較佳地,若投與不為同時,則化合物係在彼此接近之時間內投與。適當地,兩種藥物係在彼此之約24、約12、約11、約10、約9、約8、約7、約6、約5、約4、約3、約2或約1小時內投與。如本文所用,當波齊替尼及T-DM1之投與間隔小於約45分鐘時,此被視為是同時投與。
如本文所用,術語「醫藥上可接受之載劑及/或賦形劑」係指在藥理學及/或生理學上與個體及活性成分相容之載劑及/或賦形劑。醫藥上可接受之載劑包括(但不限於) pH調節劑、表面活性劑、佐劑及離子強度增強劑。例如,pH調節劑包括(但不限於)磷酸鹽緩衝溶液;表面活性劑包括(但不限於)陽離子、陰離子或非離子表面活性劑,例如Tween-80;離子強度增強劑包括(但不限於)氯化鈉。
如本文所用,「有此需要之個體」係指罹患與HER1、HER2或HER4或其任何突變體之過度表現相關聯之病症或疾病之個體或患者,其將受益於包含波齊替尼及抗HER1、HER2或HER4抗體諸如曲妥珠單抗或其藥物結合物諸如T-DM1之醫藥組合的投與。此等個體特別包括罹患HER2陽性乳癌或轉移性HER2陽性乳癌或HER2陽性胃癌之個體。適當地,癌症可為原發性乳癌,即起源於乳房之癌症。或者,癌症可為繼發性諸如轉移性乳癌,即癌症在乳房中開始並遷移至繼發部位。適當地,治療癌症之方法係針對罹患胃癌,較佳HER2陽性,更佳先前已用一種或多種化療劑治療之HER2陽性胃癌之個體。
本文使用之術語「野生型」在此項技術中所理解且係指在沒有遺傳修飾之天然群體中發生之多肽或多核苷酸序列。亦如此項技術中所理解,「突變體」包括與分別在野生型多肽或多核苷酸中發現之相應胺基酸或核酸相比具有對胺基酸或核酸之至少一個修飾之多肽或多核苷酸序列。術語突變體包括單核苷酸多型性(SNP),其中與最普遍發現之(野生型)核酸股相比,核酸股之序列中存在單鹼基對區別。為HER1、HER2或HER4之野生型或突變體或具有HER1、HER2或HER4基因之擴增或具有HER1、HER2或HER4蛋白之過度表現之癌症係藉由已知方法鑑定。
如本文所用,術語「抗體」係指通常由兩對多肽鏈(每對具有輕(L)鏈及重(H)鏈)組成之免疫球蛋白。抗體輕鏈可分類為κ輕鏈或λ輕鏈。重鏈可分類為μ、δ、γ、α或ε,及抗體之同型分別定義為IgM、IgD、IgG、IgA及IgE。在輕鏈及重鏈中,可變區及恆定區係經由具有約12個或更多個胺基酸之「J」區連接,並且重鏈另外含有具有約3個或更多個胺基酸之「D」區。各重鏈由重鏈可變區(VH)
及重鏈恆定區(CH
)組成。重鏈由3個結構域(CH1、CH2及CH3)組成。各輕鏈由輕鏈可變區(VL
)及輕鏈恆定區(CL
)組成。抗體之恆定區可介導免疫球蛋白結合宿主組織或因子,包括免疫系統之各種細胞(例如效應細胞)及經典補體系統之第一組分。
如本文所用,術語抗體之「抗原結合片段」係指含有全長抗體片段之多肽,該片段保留與全長抗體所結合之相同抗原特異性結合之能力,及/或與全長抗體競爭特異性結合至該抗原。醫藥組合
根據本揭示內容,醫藥組合包含波齊替尼及抗HER1、抗HER2或HER4抗體或其抗原片段。適當地,抗體係選自由曲妥珠單抗、西妥昔單抗(HER4抗體)、MA1-861、HFR1、H4.77.16、其抗原性片段或結合物。適當地,抗體係曲妥珠單抗、西妥昔單抗或曲妥珠單抗依坦辛(T-DM1),且包含波齊替尼或其任何醫藥上可接受之鹽。醫藥上可接受之鹽可包括(但不限於)無機或有機酸之酸加成鹽。無機酸加成鹽之實例可包括鹽酸、氫溴酸、硫酸、二硫酸、硝酸、磷酸、高氯酸或溴酸之鹽;有機酸加成鹽之實例可包括以下之鹽:甲酸、乙酸、丙酸、草酸、琥珀酸、苯甲酸、檸檬酸、馬來酸、丙二酸、蘋果酸、酒石酸、葡萄糖酸、乳酸、杏仁酸、乙醇酸、丙酮酸、戊二酸、抗壞血酸、棕櫚酸、羥基馬來酸、羥基苯甲酸、苯乙酸、肉桂酸、甲磺酸、苯磺酸、甲苯磺酸、乙二磺酸、龍膽酸(gestisic acid)、富馬酸、乳糖酸、水楊酸、鄰苯二甲酸、撲酸(embonic acid)、天冬胺酸、穀胺酸、樟腦磺酸、苯磺酸(besylic acid)或乙基水楊酸(阿司匹林)。
治療有效量之本發明組合物之投與優於個別組分化合物之優點在於與治療有效量之組分化合物之個別投與相比,該等組合提供一種或多種以下改善之性質:i)比最具活性之單藥劑更強之抗癌效應,ii)協同或高度協同之抗癌活性,iii)提供增強之抗癌活性及降低之副作用概況之給藥方案,iv)毒性效應概況之減少,v)治療窗口之增加,vi)一種或多種組分化合物之生物利用度之增加,或vii)相對於個別組分化合物,細胞凋亡增加。
本發明亦關於波齊替尼與抗HER2抗體或其抗原結合片段組合或波齊替尼與該抗體部分之結合物製備套組之用途,其中該套組用於在向患者投與有效量之該組合之前偵測樣品中HER2之存在或HER2之含量。該套組視需要包含用於偵測患者生物樣品中HER2之存在或HER2之含量之說明書。醫藥組合之投與
幾種惡性腫瘤,包括肺癌、乳癌、胃癌、結腸直腸癌、頭頸癌及胰臟癌,係與EGFR受體家族成員之突變或過度表現相關。波齊替尼已證明在治療各種此類癌症(包括肺癌、胃癌、乳癌及頭頸癌)中具有治療活性。
本發明另外提供治療癌症之方法,其包括向有此需要之個體投與如本文所述之醫藥組合物。適當地,向有此需要之個體投與治療有效量之波齊替尼及抗HER2抗體之醫藥組合,該抗HER2抗體以可高達0.1 nmol/L之抗原親和力常數識別HER2細胞外結構域抗原決定基。適當地,抗HER2抗體係人類化單株抗體,諸如曲妥珠單抗,其識別HER2細胞外結構域IV近膜抗原決定基,且其抗原親和力常數可高達0.1 nmol/L。適當地,該抗體識別由區段IV之C端之3個環(557-561、570-573及593-603)組成之抗原決定基。適當地,該抗體可為人類化雙特異性抗HER2抗體或其雙特異性抗原結合片段,其包含一個含有曲妥珠單抗之重鏈及輕鏈之可變區之抗原結合位點,及另一個含有帕妥珠單抗(pertuzumab)之重鏈及輕鏈之可變區之抗原結合位點。該雙特異性抗體較佳識別HER2細胞外結構域IV及II。適當地,該抗體可為嵌合(小鼠/人類)單株抗體,諸如西妥昔單抗。
適當地,醫藥組合係波齊替尼及曲妥珠單抗依坦辛結合物(T-DM1)之組合。波齊替尼可以0.1mg至50mg之量投與。T-DM1可以0.5至10mg/kg患者體重之量投與。較佳地,T-DM1係以1.5至5.5mg/kg體重之量投與。該組合可另外包含口服紫杉醇。
或者,該抗體係西妥昔單抗,其為用於治療轉移性結直腸癌、轉移性非小細胞肺癌及頭頸癌之一種表皮生長因子受體(EGFR)抑制劑。西妥昔單抗係藉由靜脈內輸注提供之嵌合(小鼠/人類)單株抗體,其由醫藥公司Bristol-Myers Squibb在美國及加拿大以商品名ErbituxTM
分銷,且由醫藥公司Merck KGaA在美國及加拿大以外分銷。在日本,Merck KGaA、Bristol-Myers Squibb及Eli Lilly共同分銷。作為除波齊替尼/T-DM1組合之另一種藥劑,西妥昔單抗可以100 mg/m2
至500 mg/m2
身體表面積之量投與。
長春瑞濱(NVB)(尤其以商標名NavelbineTM
銷售)係用於治療多種類型癌症之化療藥物。此包括乳癌及非小細胞肺癌。其係藉由靜脈內注射或口服提供。長春瑞濱係長春花生物鹼家族。不希望受任何特定理論束縛,據信長春瑞濱藉由破壞微管之正常功能且由此停止細胞分裂而起作用。作為除波齊替尼/T-DM1組合之另一種藥劑,長春瑞濱可以0.5 mg/m2
至50mg/m2
身體表面積之量投與。
紫杉醇(PTX)(尤其以商標名TaxolTM
銷售)係用於治療多種癌症之化療藥物。此包括卵巢癌、乳癌、肺癌、卡波西肉瘤(Kaposi sarcoma)、宮頸癌及胰臟癌。其係藉由靜脈內注射提供。作為除波齊替尼/T-DM1組合之另一種藥劑,紫杉醇可以100 mg/m2
至300 mg/m2
身體表面積之量投與。
適當地,波齊替尼及T-DM1之組合可另外包括有絲分裂抑制劑。有絲分裂抑制劑可選自BT-062、HMN-214、甲磺酸艾日布林(eribulin mesylate)、長春地辛、EC-1069、EC-1456、EC-531、韋他福利德(vintafolide)、2-甲氧基雌二醇、GTx-230、克羅布林(crolibulin)、D1302A-類美登素結合物、IMGN-529、羅佛單抗-莫登素(lorvotuzumab mertansine)、SAR-3419、SAR-566658、IMP-03138、拓撲替康/長春新鹼組合、BPH-8、福他布林緩血酸胺(fosbretabulin tromethamine)、雌莫司汀磷酸鈉(estramustine phosphate sodium)、長春新鹼、長春氟寧(vinflunine)、長春瑞濱、RX-21101、卡巴他賽(cabazitaxel)、STA-9584、長春鹼、埃坡黴素A (epothilone A)、帕土匹龍(patupilone)、伊沙匹隆、埃坡黴素D (Epothilone D)、紫杉醇、多西紫杉醇、DJ-927、圓皮海綿內酯(discodermolide)、艾榴塞洛素(eleutherobin)及其醫藥上可接受之鹽或其組合。例如,該組合可另外包括紫杉烷、長春花生物鹼或其組合。長春花生物鹼可為至少一種選自長春鹼、長春新鹼、長春地辛及長春瑞濱之藥物。紫杉烷可為紫杉醇或多西紫杉醇。適當地,波齊替尼及T-DM1之組合可另外包括紫杉醇或長春瑞濱。較佳地,波齊替尼及T-DM1之組合另外包括紫杉醇。
適當地,波齊替尼及T-DM1之組合可另外包括mTOR抑制劑。mTOR抑制劑可選自佐他莫司(zotarolimus)、烏米莫司(umirolimus)、替西羅莫司(temsirolimus)、西羅莫司(sirolimus)、西羅莫司NanoCrystalTM
、西羅莫司TransDermTM
、西羅莫司-PNP、依維莫司(everolimus)、拜爾莫司A9 (biolimus A9)、地磷莫司(ridaforolimus)、雷帕黴素(rapamycin)、TCD-10023、DE-109、MS-R001、MS-R002、MS-R003、Perceiva、XL-765、奎納克林(quinacrine)、PKI-587、PF-04691502、GDC-0980、達托里斯(dactolisib)、CC-223、PWT-33597、P-7170、LY-3023414、INK-128、GDC-0084、DS-7423、DS-3078、CC-115、CBLC-137、AZD-2014、X-480、X-414、EC-0371、VS-5584、PQR-401、PQR-316、PQR-311、PQR-309、PF-06465603、NV-128、nPT-MTOR、BC-210、WAY-600、WYE-354、WYE-687、LOR-220、HMPL-518、GNE-317、EC-0565、CC-214、ABTL-0812及其醫藥上可接受之鹽或其組合。例如,波齊替尼及T-DM1之組合可另外包括雷帕黴素。雷帕黴素可呈注射劑之形式。雷帕黴素(亦稱為西羅莫司)為由細菌吸水鏈黴菌(Streptomyces hygroscopicus
)產生之化合物。雷帕黴素可以0.5 mg/m2
至10 mg/m2
身體表面積之量投與。
適當地,波齊替尼及T-DM1之組合可另外包括抗代謝物。抗代謝物可選自卡培他濱(capecitabine)、5-氟尿嘧啶、吉西他濱(gemcitabine)、培美曲塞(pemetrexed)、胺甲喋呤、6-巰基嘌呤、克拉屈濱(cladribine)、阿糖胞苷(cytarabine)、多西氟尿苷(doxifludine)、氟尿苷(floxuridine)、氟達拉濱(fludarabine)、羥基脲(hydroxycarbamide)、癸二嗪(decarbazine)、羥基脲及天冬醯胺酶。例如,波齊替尼及T-DM1之組合可另外包括5-氟尿嘧啶。5-氟尿嘧啶可呈注射劑之形式。5-氟尿嘧啶可以100 mg/m2
至3,000 mg/m2
身體表面積之量投與。
氟尿嘧啶(5-FU) (尤其以商品名AdrucilTM
出售)係用於治療癌症之嘧啶類似物。藉由靜脈內注射,其用於治療結腸癌、食道癌、胃癌、胰臟癌、乳癌及宮頸癌。作為局部乳膏,其用於基底細胞癌。其作用機制尚不完全清楚,但是,不希望受任何特定理論束縛,據信涉及阻斷胸苷酸合成酶之作用並因此停止DNA之產生。
適當地,波齊替尼及T-DM1之組合可另外包括基於鉑之抗腫瘤藥。基於鉑之抗腫瘤藥可選自順鉑、卡鉑、雙環鉑、依他鉑(eptaplatin)、洛鉑(lobaplatin)、米鉑(miriplatin)、奈達鉑(nedaplatin)、奧沙利鉑(oxaliplatin)、吡鉑(picoplatin)及沙鉑(satraplatin)。例如,波齊替尼/T-DM1組合可另外包括順鉑。順鉑可呈注射劑之形式。順鉑可以1 mg/m2
至100 mg/m2
身體表面積之量投與。不希望受任何特定理論束縛,據信順鉑部分地藉由與DNA結合並抑制DNA複製起作用。
治療有效量之本發明組合係投與給人類。通常,本發明之投與藥物之治療有效量取決於許多因素,包括例如個體之年齡及體重、需要治療之確切病症、病症之嚴重程度、調配物之性質及投與途徑。最終,治療有效量將由主治醫生決定。
適當地,化合物係在各治療週期中同時或依序投與。當不同時投與時,其等均在彼此之約24、約12、約11、約10、約9、約8、約7、約6、約5、約4、約3、約2或約1小時內投與,在此情況下,指定時間段將為約24、12、11、10、9、8、7、6、5、4、3、2或1小時。如本文所用,對於雙成分藥物組合(例如波齊替尼及T-DM1),間隔小於約45分鐘之波齊替尼及T-DM1之投與被視為是同時投與。
適當地,在各治療週期中,兩種化合物在指定時間內投與至少1天、至少2天、至少3天、至少5天、至少7天、至少14天、至少21天或至少30天,在此情況下,治療週期之持續時間至少為1、2、3、5、7、14、21或30天。當在治療過程中,兩種化合物在指定時間內投與超過30天時,該治療被視為慢性治療,並持續到改變事件,例如癌症狀態之重新評估或患者之病症或一種或多種嚴重不良事件之改變,保證對方案進行修改。
適當地,在例如波齊替尼及T-DM1之藥物組合之治療過程中,兩種組成藥物在指定時間段內投與至少1天,隨後單獨投與波齊替尼至少額外1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25、26、27、28或29天,因此在該實施例中,治療持續時間分別為至少2至30天。適當地,治療週期為21天±3天。適當地,治療週期為21天。
此外,本文設想在波齊替尼及另一組成藥物中之一者與另一藥物之依序投與之間之藥物假期或休止期。如本文所用,藥物假期(休止期)為在依序投與波齊替尼及另一組成藥物中之一者之後且在投與另一種之前(沒有投與波齊替尼及其他組成藥物之情況)之一段時間。適當地,藥物假期為選自以下之天數:1天、2天、3天、4天、5天、6天、7天、8天、9天、10天、11天、12天、13天及14天。
應理解,各治療週期之後可為一個或多個重複給藥週期,或者之後可為替代給藥方案,且另外應理解,藥物假期可在重複給藥或替代給藥方案之前進行。
當個體罹患具有HER2外顯子20突變之乳癌時,HER2外顯子20突變可適當地包含HER2框內外顯子20插入突變、HER2外顯子20點突變或兩者。HER2框內外顯子20插入突變可選自由A775_G776insYVMA、G776_V777insVC、P780_Y781insGSP及其組合組成之群。HER2外顯子20點突變可選自由L775S、G776V、V777L及其組合組成之群。適當地,HER2外顯子20突變不為T790M點突變。
野生型或突變體HER1、HER2及HER4腫瘤細胞可藉由DNA擴增及定序技術、DNA及RNA偵測技術(包括(但不限於)分別北方及南方墨點法,及/或各種生物晶片及陣列技術或原位雜交)鑑定。野生型及突變體多肽可藉由多種技術偵測,該等技術包括(但不限於)免疫診斷技術諸如ELISA、西方墨點法或免疫細胞化學。
較佳地,該方法包括向有需要之個體投與包含波齊替尼及T-DM1及視需要之其他化療劑之藥物組合。較佳地,可選化療劑包含紫杉醇。
適當地,篩選患者以評估其HER1、HER2或HER4狀態。熟習此項技術者將理解,本文所述藥物組合之每日劑量將由醫生在合理之醫學判斷範圍內決定。任何特定患者之具體劑量將取決於多種因素,包括所治療之癌症及其嚴重程度;在藥物組合物中調配之波齊替尼之活性;所用之特定藥物組合物;有此需要之個體之年齡、體重、一般健康、性別及飲食;投與時間;每次投與之規定劑量數;治療之持續時間;與所用特定藥物組合物組合或吻合使用之藥物;及醫學領域眾所周知之類似因素。
例如,在此項領域中經過訓練之技術人員之技能範圍內,以低於達成所需治療效果所需之劑量開始,並逐漸增加劑量直至達到所需效果。適當地,與個別地投與時接受標準劑量之波齊替尼或抗HER1、抗HER2或抗HER4抗體之個體相比,接受本發明組合之個體表現改善之毒性概況。適當地,改善之毒性涉及心臟毒性之降低,例如肌鈣蛋白I增加至高於所使用檢定之正常範圍之參考上限(URL)之99%,或任何3級心血管毒性。適當地,改善之毒性涉及血液學毒性之改善。例如,與接受個別藥物治療之個體相比,接受組合療法之個體顯示在血小板減少症及中性粒細胞減少症之速率方面的統計學改善。
適當地,接受組合療法之個體在發展非血液學毒性諸如腹瀉、皮疹、黏膜炎、疲勞、電解質或肝毒性概況方面表現出改善且有利地降低之速率。
現在將參考以下實例更詳細地描述實施例。然而,該等實例無意限制實施例之範圍。實例 實例 1 :治療 HER2 陽性乳癌之方法
通常,鑑定罹患乳癌之女性患者,進行基線成像,獲得乳房組織用於腫瘤基因分型,該患者經歷基於腫瘤分型之治療期,評估治療並視需要另外繼續或修改。
通過免疫組織化學(IHC)指定為IHC 3+或IHC 2+,與證實螢光原位雜交(FISH)確認患者為HER2過度表現或基因擴增之腫瘤。IHC測試提供0至3+之分數,其量測乳癌組織樣品中細胞表面上HER2受體蛋白之量。若分數為0至1+,則將組織指定為「HER2陰性」。若分數為2+,則將組織指定為「臨界性」。分數3+指定為「HER2陽性」。
患者接受21天週期±3天治療,第1天使用3.6 mg/kg T-DM1 IV輸注,及第1至21天以選自每天6 mg、8 mg、10 mg、12 mg或16 mg之比率之單一劑量口服波齊替尼。可投與每天24 mg之高口服波齊替尼劑量,但是給藥方案可包括1週休止期,即,在21天週期之第1至14天投與24 mg/天,隨後在第15至21天休止期。繼續此等21天週期,直至另外指示疾病進行、死亡或不可耐受之不良事件(AE)為止。
進行1b期、開放標籤、多中心研究以確定當在罹患晚期或轉移性HER2陽性乳癌之女性中投與標準劑量之T-DM1時,波齊替尼之最大耐受劑量(MTD)或最大投與劑量(MAD)。在用於療效評估之該研究之第2部分中,組合使用在研究之第1部分中鑑定之波齊替尼劑量與標準起始劑量之T-DM1(在各21天週期之第1天,3.6 mg/kg IV)。
因此,該研究之第1部分係用於劑量發現。組群1在各週期第1天以8 mg口服波齊替尼,與標準起始劑量之T-DM1 (3.6 mg/kg IV)組合開始,及隨後每日口服8 mg波齊替尼。基於「3+3」設計,波齊替尼劑量基於當前劑量組群之第1週期期間劑量限制性毒性(DLT)之發生而遞增/遞減繼續進行。
DLT定義為在第一個治療週期中發生之任何以下治療相關毒性:
心臟毒性:
肌鈣蛋白I增加高於所使用分析之正常範圍之參考上限(URL)之99%或任何3級心血管毒性
血液學毒性:
3級血小板減少症伴出血;
4級中性粒細胞減少症> 7天或3級發熱性中性粒細胞減少症
非血液學毒性:
在藥物治療期間,3級或更高級別腹瀉,持續>3天,或伴有≥100.5℉ (38.1℃)之發熱至少2天或嚴重脫水;
4級皮疹或黏膜炎;
≥3級疲勞≥1週;
根據Hy定律之肝毒性證據(ALT或AST≥3×ULN,總膽紅素> 2×ULN,無既往病毒性肝炎、肝臟疾病或肝轉移;經招募罹患肝轉移之患者,ALT或AST> 8×ULN或AST或ALT> 5×ULN持續≥14天;
≥3級電解質異常持續>72小時,除非患者具有臨床症狀,在此種情況下,不論持續時間,所有≥3級電解質異常都應算作DLT;與胰腺炎之症狀或臨床表現不相關之≥3級澱粉酶或脂肪酶升高無需計為DLT;
任何其他≥3級治療相關非血液學毒性;
不清楚由於潛在疾病或外來原因造成之任何死亡。
毒性係使用國家癌症研究所(National Cancer Institute,NCI)不良事件通用術語標準(Common Terminology Criteria for Adverse Events,CTCAE)量表(版本4.03),基於不良事件之等級加以評定。
在1b期第1部分中,在各週期第1天之波齊替尼之劑量與T-DM1 (3.6 mg/kg IV)之標準起始劑量之組合係使用「3+3」設計確定,最多3個劑量水平,以8 mg/天開始測試。基於當前劑量組群之第1週期期間之劑量限制性毒性(DLT)之發生,下一劑量組群之波齊替尼劑量遞增/遞減繼續進行。完成第1週期之患者在該組群劑量下繼續治療,直至治療中斷。四個可能組群包括8、10及12 mg/天之波齊替尼,加上減低劑量之6 mg/天之波齊替尼。
在1b期研究之第2部分,約10患者在MTD/MAD下進行治療以確認該組合之安全劑量並評估初步療效。對所有患者之治療持續進行直至疾病進展、不可接受之毒性或繼續研究治療不符合患者之最佳利益。
在各21天週期期間,有資格參與之患者接受指定劑量之波齊替尼,口服,每日一次,每天早上大約在相同時間連續用一杯水及早餐。在各治療週期之第1天投與3.6 mg/kg IV之T-DM1。在提供T-DM1之當天,波齊替尼係在輸注結束後依次提供。
在3個治療週期後,每9週±14天評定腫瘤反應。
實例 2 :治療 HER2 陽性乳癌之方法 —— 劑量方案、療效及安全性 / 耐受性
使用2期、開放標籤、多中心研究以建立劑量方案並評估波齊替尼在已接受過至少兩種先前HER2導向治療方案(包括曲妥珠單抗及T-DM1)之罹患HER2陽性轉移性乳癌(MBC)之患者中之初步療效及安全性/耐受性。波齊替尼在21天治療週期中投與24 mg/天(持續2週,接著1週休止期)、16 mg/天(連續每日給藥)或12 mg/天(連續每日給藥)之劑量。毒性係使用國家癌症研究所(NCI)不良事件通用術語標準(CTCAE)量表(版本4.03)基於不良事件之等級評估。
關於另外包括另一種藥劑之組合治療,在乳癌細胞之情況下,當波齊替尼與紫杉醇、順鉑或5-FU組合時,在HER2-過度表現且雌激素受體(ER)陰性之BT-474細胞中已觀測到高協同效應。當波齊替尼與曲妥珠單抗組合時,在等於或低於單獨波齊替尼之GI50
之一些濃度展現弱協同效應,其中GI50
為導致癌細胞增殖減少50%之藥物濃度。當將波齊替尼與長春瑞濱組合時,在等於或低於單獨波齊替尼之GI50
之濃度未觀測到協同效應。類似地,當長春瑞濱與波齊替尼組合時,在HER2-過度表現及ER陰性之SK-BR-3細胞中觀測到足夠之效應指示協同作用。然而,波齊替尼與長春瑞濱之組合在HER2過度表現、ER陽性以及曲妥珠單抗耐藥性之MDA-MB-361細胞中在一些濃度顯示協同效應,且此組合在非HER1及HER2過度表現及ER陽性之MCF-7細胞中在每個濃度顯示協同作用。此外,在MDA-MB-468細胞(其為HER2陰性、ER陰性及HER1過度表現之三陰性乳癌細胞)中波齊替尼及長春瑞濱之組合在一些濃度觀測到協同效應。在MBA-MB-453細胞(其為在曲妥珠單抗耐藥性之乳癌細胞中HER2過度表現之細胞)中,當紫杉醇、5-FU、順鉑或曲妥珠單抗與波齊替尼組合時,在等於或低於單獨波齊替尼之GI50
之濃度觀測到極佳協同效應。
當波齊替尼與5-FU組合時,在TE細胞(其為HER2過度表現之食道癌細胞系)中,波齊替尼與其他藥物組合之協同效應亦極佳。此外,當波齊替尼與曲妥珠單抗組合時,在N-87細胞(其為HER2過度表現之胃癌細胞系)中,在一些濃度觀測到協同效應。
因此,波齊替尼及T-DM1之組合(另外包含其他靶抗癌劑或細胞毒性抗癌劑,較佳地其中癌與HER1、HER2或HER4或HER1、HER2或HER4之突變體之過度表現或擴增相關聯)在諸如乳癌、胃癌、肺癌及食道癌之癌症中將高度有效,且將有效地抑制對習知治療劑具有耐藥性之癌症。適當地,癌症為HER2陽性乳癌。實例 3 :治療 HER2 陽性晚期胃癌之方法
在韓國的11個治療中心進行一項前瞻性I/II期研究。招募HER2陽性GC患者,該等患者先前已接受過一線或多線化療。招募之患者每天接受一次口服波齊替尼(8 mg或12 mg),持續14天,接著休止7天。在每3週第1天與波齊替尼同時投與紫杉醇(175 mg/m2
輸注)及曲妥珠單抗(8 mg/kg速效劑量,隨後6 mg/kg輸注)。
方法
患者
。主要合格標準包括:年齡≥19歲之患者;組織病理學證實局部晚期不可切除、復發性或轉移性胃腺癌(包括食道胃交界處之腺癌);HER2免疫組織化學(IHC)3+或HER2 IHC 2+及HER2螢光原位雜交(FISH)+;藉由實體腫瘤中之反應評估標準(Response Evaluation Criteria in Solid Tumors,RECIST,版本1.1)存在一個或多個可量測之病變;前一線化療(包括氟嘧啶或鉑),不論曲妥珠單抗暴露;及足夠之骨髓及肝功能。主要排除標準包括:對含有Cremophor®
EL及曲妥珠單抗之藥物過敏之病史;先前暴露至紫杉烷,並有症狀性中樞神經系統轉移。
此研究係根據赫爾辛基宣言(Declaration of Helsinki)及關於協調良好臨床實踐指南之國際會議(International Conference on Harmonization Good Clinical Practice Guidelines)進行,並得到各參與中心之機構審查委員會(Institutional Review Board)批准。所有患者在招募前均提供書面知情同意書。
治療程序
。各21天週期由在第1天每天口服投與波齊替尼一次,持續14天,與紫杉醇(175 mg/m2
輸注)及曲妥珠單抗(8 mg/kg速效劑量,接著6 mg/kg輸注)組合組成。在該研究之I期部分中,測試漸增劑量之波齊替尼(8 mg、12 mg或16 mg)以確定波齊替尼與紫杉醇及曲妥珠單抗之組合之RP2D。在各波齊替尼劑量下評估6名患者之DLT。若在≤1名患者中觀測到DLT,則劑量遞增持續至下一劑量。若在≥2名患者中觀測到DLT,則停止劑量遞增並將MTD確定為≤1患者中發生DLT之最高水平。在該研究之II期部分中,32名患者接受RP2D之波齊替尼與紫杉醇及曲妥珠單抗之組合治療。
安全分析及療效
。不良事件(AE)及TEAE係使用國家癌症研究所-不良事件通用術語標準(版本4.03)評估。DLT定義為≥3級非血液學毒性(禿髮除外);不管最大劑量之抗腹瀉及/或止吐藥物(如適用),≥3級腹瀉、噁心及嘔吐;及4級中性粒細胞減少症持續≥7天,3-4級中性粒細胞減少症伴發熱或感染,4級血小板減少症及3級血小板減少症持續7天,或伴有出血或需要輸血。在基線、在前3個週期之第1天及此後每3個週期進行左心室射血分數(LVEF)評定。所有接受至少一個劑量波齊替尼之患者都包括在安全性分析中。腫瘤反應係根據研究者評定,使用RECIST版本1.1,每6週藉由胸部、腹部及骨盆之CT或MRI來評估。
統計分析
。I期之主要目標為欲評估波齊替尼之安全性及耐受性,並確定與紫杉醇及曲妥珠單抗組合使用時波齊替尼之MTD。II期部分之主要目標為欲評估波齊替尼與紫杉醇及曲妥珠單抗之組合之客觀反應率(ORR)。次要目標為欲評估安全性及耐受性、無進展存活期(PFS)、腫瘤進展之時間(TTP)及總反應持續時間(DOR)。
對於II期,吾人假設ORR<5%無效,且ORR>20%將被視為具有臨床意義。樣本大小係使用Simon之2階段極小極大設計來計算,檢定力為80%,顯著性水平為5%。在總共27個目標個體中,第1階段需要13個。若13名患者均無腫瘤反應,則該研究計劃提前終止。然而,若觀測到至少1個反應,則該研究將招募另外14個患者。結果 I 期
MTD 之測定
。7名患者以劑量水平1 (波齊替尼8 mg)招募,然而一名患者由於在第1週期完成之前失訪而無法評估DLT。在剩餘6名患者中,在1名中觀測到DLT (4級中性粒細胞減少症)。在劑量水平2 (波齊替尼12 mg)下,招募5名患者,且在2名中觀測到DLT (一名患有4級中性粒細胞減少症,及另一名患有發熱性中性粒細胞減少症及4級中性粒細胞減少症)。因此,根據上述標準,確定8 mg波齊替尼為MTD。
毒性及劑量調整
。安全性分析設定由I期之12名患者組成。表2匯總TEAE。所有12名患者(100%)均經歷≥1個TEAE,其中在11名患者(91.7%)中觀測到≥3級毒性。與研究中斷相關之TEAE發生在3名患者(25.0%)中。據報導1名患者(8.3%)中有導致死亡之TEAE (表2)。最常見之波齊替尼相關AE係腹瀉、皮疹、口腔炎、瘙癢及食慾不振(表3)。分別在9名(75%)及2名(16.7%)患者中觀測到3級或更高級別中性粒細胞減少症及發熱性中性粒細胞減少症(補充表1)。對6名患者中之1名(14.3%)進行波齊替尼劑量減少(自8至6 mg)。分別對2名(28.6%)及1名(14.3%)患者進行劑量減少及紫杉醇中斷 (補充表2)。
表2.治療-緊急不良事件(TEAE)之總體匯總
表3.安全性概況:與波齊替尼相關之不良事件(≥10%之患者)
補充表1.與波齊替尼相關聯之最常發生(≥10%)且≥3級TEAE之發生率
補充表2.劑量調整
療效
。總共11名患者可用於評估波齊替尼之療效。在4名患者中觀測到客觀反應(33.3%;95% CI,9.9-65.1) (表4)。所有四個人均具有部分反應。疾病控制率(DCR;PR + SD)為66.7% (95% CI,34.9-90.1)。中位PFS及OS分別為17.7週(95% CI,5.4-30.2)及30.6週(95% CI,12.2-195.0) (表5及圖1)。。
表4.腫瘤反應之匯總
CI,置信區間。若未收集最後一次投與日期,則使用研究結束日期。I期中8 mg及12mg的患者數分別為2及2。及II期(8 mg)中的患者數為7。根據總反應持續時間計算總共11個。II 期
參見上表。
II期納入總共32名患者。20名患者(63%)接受減低劑量之波齊替尼。見上面之補充表2。
安全性分析
。3級或更高級別之TEAE中性粒細胞減少症及發熱性中性粒細胞減少症分別在4名(12.5%)及3名(9.4%)患者中發展(補充表1)。最常見之波齊替尼相關TEAE係腹瀉、皮疹、口腔炎及食慾下降,類似於在I期獲得之結果(表3)。在13名患者(40.6%)中觀測到3級或更高級別腹瀉(補充表1)。由於治療相關毒性,4名患者(12.5%)在第一次評定前中斷該研究。沒有3級或4級左心室收縮功能障礙(LVSD)。20名(62.5%)患者接受減低劑量之波齊替尼。對12名患者(37.5%)投與減低劑量之紫杉醇,3名患者(9.4%)中斷紫杉醇(補充表2)。
療效
。20名患者(62.5%)出現腫瘤收縮(圖1)。在7名患者中觀測到確認之反應(21.9%;95% CI,9.3-40.0)。2名患者(6.3%)具有完全反應,及5名(15.6%)具有部分反應。DCR為71.9% (95% CI,53.3-86.3) (表4)。中位PFS為13.0週(95% CI,9.8-21.9) (表5,圖1及3)。中位OS為29.5週(95% CI,17.9-59.2) (表5,圖1)。中位TTP及DOR分別為15.0週(95% CI,10.0-23.1)及26.8週(95% CI,17.2-71.8) (表5)。當研究曲妥珠單抗暴露之臨床療效時,曲妥珠單抗預治療及曲妥珠單抗初治患者之ORR分別為12.5%及50.0% (表4)。曲妥珠單抗預治療之患者之中位OS及PFS分別為29.5週(95% CI,17.9-40.9)及13.0週(9.8-18.7),在曲妥珠單抗初治患者中為42.6週(95% CI,3.0-111.5)及18.7週(95% CI),3.0-) (表5)。討論
在此項前瞻性、多中心、開放標籤I/II期研究中,波齊替尼8 mg與紫杉醇加曲妥珠單抗之組合在罹患晚期HER2陽性胃癌(GC)之先前經治療患者中顯示可控之毒性及有前景之療效。據吾人所知,本研究為首次評估在HER2陽性腫瘤中與化療劑及曲妥珠單抗之組合之泛HER抑制劑。
在先前I期研究中,波齊替尼MTD確定為24 mg/天,間歇給藥(14天給藥及7天休止)及18 mg/天連續給藥。在本研究之I期部分中,波齊替尼之MTD確定為8 mg/天,此遠低於單藥療法之24 mg/天之波齊替尼MTD。吾人之研究中最常觀測到之TEAE為腹瀉、皮疹、口腔炎及瘙癢。在吾人之研究中,所有患者至少經歷一個TEAE,其頻率與波齊替尼單藥療法之I期試驗中報導之頻率相似。與I期單藥療法試驗相比,吾人之研究中之所有DLT均報告為4級中性粒細胞減少症或伴有4級中性粒細胞減少症之發熱性中性粒細胞減少症,而非腹瀉。
在上述I期試驗中,據報導,波齊替尼單藥療法之ORR及中位PFS分別為16%及12.0週(間歇給藥方案)及21%及9.0週(連續給藥方案)。另一種泛HER抑制劑達克替尼(dacomitinib)作為單藥療法在HER2陽性GC中產生7.4%之ORR (95% CI,0-17.5)及2.1個月之中值PFS (95% CI,2.3-3.4)。考慮到吾人之研究之ORR及中位PFS,此等結果表明泛HER抑制劑與化療之組合可比單獨使用泛HER抑制劑更強效。
HER2受體之雙重阻斷已成為HER2陽性乳癌之標準醫護。帕妥珠單抗與多西紫杉醇加曲妥珠單抗之組合顯著增加HER2陽性乳癌之OS。然而,與HER2陽性乳癌相比,帕妥珠單抗與化療之組合並未延長HER2陽性GC中之OS。此發現結果指示HER2陽性GC中雙重阻斷之療效可與HER2陽性乳癌中之療效不同。然而,甚至在活體外,使用拉帕替尼(lapatinib)及曲妥珠單抗之雙重阻斷顯示對HER2-擴增之GC細胞之高度協同抗腫瘤活性。在目前研究中,波齊替尼與曲妥珠單抗之組合顯示良好之腫瘤反應,此指示此種雙重阻斷策略(包括泛HER抑制劑)將成為HER2陽性GC中作為補救治療之有前景治療選項。
進展後繼續抗HER2靶向療法係HER2陽性乳癌中普遍接受之治療策略。一項回顧性研究報導,進展後曲妥珠單抗增加HER2陽性GC中之PFS及OS。然而,在一項前瞻性II期研究中,進展後曲妥珠單抗作為二線未能改善HER2陽性GC患者之PFS及ORR,這指示進展後曲妥珠單抗之作用在HER2陽性GC中仍存在爭議。
抗體-藥物結合物(ADC)為HER2陽性腫瘤中新興治療策略之一。在HER2陽性GC患者中進行曲妥珠單抗依坦辛之III期試驗,該患者先前氟嘧啶及鉑治療失敗。然而,曲妥珠單抗依坦辛並不優於紫杉醇。ORR僅為20.6% (95% CI,15.26-26.45)。DS8201a (一種新穎靶向HER2之ADC)顯示針對HER2陽性GC細胞之強效抗腫瘤活性。在I期研究中,DS8201a在對曲妥珠單抗耐藥性之HER2陽性GC患者及低HER2表現GC患者中顯示ORR為44%及DCR為78%,這指示靶向HER2之ADC將成為HER2陽性GC中之有前景補救治療。
在目前研究中,預處理活組織檢查不為強制性,因此患者係基於初始診斷時之HER2表現進行招募。然而,在HER2陽性GC中報導曲妥珠單抗之前及之後HER2表現之差異,且甚至在接受曲妥珠單抗之32%患者中觀測到HER2陽性之喪失。此等觀測結果指示,確切HER2狀態之重新評定在緊接用抗HER2靶向療法再激發之前係必要,及因此此代表吾人之研究之局限性。
總之,波齊替尼(8 mg)與紫杉醇及曲妥珠單抗之組合在接受過一線化療之HER2陽性GC患者中顯示良好之臨床療效及可控毒性。使用曲妥珠單抗與泛HER抑制劑之雙重阻斷抑制係克服曲妥珠單抗耐藥性之有前景策略。需要進一步臨床試驗以檢查波齊替尼與HER2靶向劑之療效。
總之,本發明揭示以下內容。本發明之一個態樣針對一種治療個體之癌症之方法,該方法包括向該個體投與治療有效量之波齊替尼及抗HER1、抗HER2或抗HER4抗體,其中該癌症係與HER1、HER2或HER4,或HER1、HER2或HER4之突變體之過度表現或擴增相關聯。該方法可另外包括投與至少一種選自紫杉醇、順鉑、5-氟尿嘧啶、長春瑞濱、西妥昔單抗及其任何組合之藥劑。該抗體較佳為選自由曲妥珠單抗、西妥昔單抗及其任何抗原結合片段組成之群之抗HER2抗體。該癌症可為非小細胞肺癌、乳癌、胃癌、結腸癌、胰臟癌、前列腺癌、骨髓瘤、頭癌、頸癌、卵巢癌、食道癌或轉移性細胞癌。
適當地,治療癌症之方法針對罹患乳癌或胃癌之個體。
適當地,該方法之靶癌係乳癌,其中乳癌可選自由以下組成之群:(i)具有HER1及/或HER2過度表現之雌激素受體陰性乳癌;(ii)雌激素受體-及孕酮受體-雙陽性乳癌,其中表現HER2但沒有過度表現;(iii)具有HER2過度表現之曲妥珠單抗耐藥性乳癌;及(iv)就PR、HER2及雌激素受體而言陰性的HER1-過度表現乳癌。適當地,乳癌係轉移性乳癌。該方法可另外包括自個體收集乳癌細胞之初步步驟;並評估乳癌細胞以確認HER2之過度表現,或HER2突變體之過度表現,或HER2基因之擴增,或HER2基因之突變體之擴增。適當地,評估步驟包括免疫組織化學(IHC)及證實螢光原位雜交(FISH),其中IHC可為IHC 3+或IHC 2+。
適當地,該方法之靶癌係胃癌。適當地,治療癌症之方法係針對罹患胃癌(較佳HER2陽性及更較佳先前已用一種或多種化療劑治療的HER2陽性胃癌)之個體。
本發明之另一態樣係針對一種治療有此需要之個體之乳癌之方法,其中該乳癌係與HER2之過度表現或擴增,或HER2之突變體之過度表現或擴增相關聯,該方法包括以下步驟:a)在21天週期 ± 3天內,i)投與單一劑量之T-DM1,範圍為1.5-5.5 mg/kg;及ii)投與每日劑量之波齊替尼,範圍為0.5-50 mg/天;及b)視需要重複該週期。適當地,T-DM1係藉由靜脈內(IV)輸注投與。適當地,T-DM1標準劑量為3.6 mg/kg。適宜地,波齊替尼係口服投與,且口服劑量可選自由每天一次6、8、10、12、16及24 mg組成之群。
本發明之另一態樣係針對一種改善經歷與HER2或HER2突變體之過度表現或擴增相關聯之乳癌治療之個體中之不良事件概況之方法,該方法包括以下步驟:a)在21天週期± 3天,i)投與單一劑量之T-DM1;及ii)投與每日劑量之波齊替尼;及b)視需要重複該週期,其中不良效應選自由心臟毒性、血液學毒性、腹瀉、皮疹、黏膜炎、疲勞、電解質異常及肝毒性組成之群。
本發明之另一態樣係針對一種用於治療個體之癌症之組合,其中該癌症係與HER1、HER2或HER4,或HER1、HER2或HER4之突變體之過度表現或擴增相關聯,且該組合包含治療有效量之波齊替尼及T-DM1,其中波齊替尼係口服投與及T-DM1係藉由IV輸注投與。該組合可另外包含藉由靜脈內(IV)輸注投與之治療有效量之紫杉醇。
本發明之另一態樣係針對一種治療有此需要之個體之胃癌之方法,其中該胃癌係與HER2之過度表現或擴增,或HER2之突變體之過度表現或擴增相關聯,且其中該方法包括以下步驟:a)在21天週期± 3天中,i)投與單一劑量之曲妥珠單抗,範圍為6-8 mg/kg;i)投與單一劑量之紫杉醇,範圍為105-175 mg/m2
;及iii)投與每日劑量之波齊替尼,範圍為4-16 mg/天;及b)視需要重複該週期。較佳地,曲妥珠單抗係在第1天藉由靜脈內(IV)輸注投與。較佳地,曲妥珠單抗標準劑量係8 mg/kg速效,接著6 mg/kg輸注。較佳地,紫杉醇係在第1天藉由靜脈內(IV)輸注投與。適當地,紫杉醇標準劑量係175 mg/m2
輸注。適宜地,波齊替尼係口服投與14±3天。適當地,波齊替尼之口服劑量選自由每天一次4、6、8、10、12及16 mg組成之群。適當地,在投與14天波齊替尼之後接著7天的休止期。
應瞭解,文中描述之實施例應僅視為說明性,而不限制本發明之範圍。各實施例內之特徵或態樣之描述通常應視為可用於其他實施例中之其他類似特徵或態樣。一般技術者應瞭解,在不脫離由隨附申請專利範圍限定之揭示內容之精神及範圍之情況下,可在其中進行形式及細節上之各種改變。
圖1A及1B顯示組合之I期及II期患者之中位無進展存活期曲線(1A)及中位總存活期曲線(1B)。
圖2A顯示組合之I期及II期之靶病變之腫瘤直徑之最佳百分比變化之瀑布圖(Waterfall Plot) (2A);圖2B僅顯示II期之瀑布圖。
圖3顯示實例3之II期部分之無進展存活期之游泳者圖(Swimmer plot)。治療持續時間:[(根據事件之發生或最後一次給藥之日期)-首次投與之日期+1]/(365.25/52)。若未收集最後一次投與日期,則使用研究結束日期。最佳總體反應(BOR)顯示在每個研究持續時間欄之右側。[]:確認BOR。若未指定,BOR及確認之BOR係相同。
Claims (37)
- 一種波齊替尼(poziotinib)製備用於治療個體癌症之藥物之用途,其中該藥物包含抗HER1、抗HER2或抗HER4抗體或與其組合使用, 其中該癌症係與HER1、HER2或HER4,或HER1、HER2或HER4之突變體之過度表現或擴增相關,且 其中該癌症係非小細胞肺癌、乳癌、結腸癌、胃癌、胰臟癌、前列腺癌、骨髓瘤、頭癌、頸癌、卵巢癌、食道癌或轉移性細胞癌。
- 如請求項1之用途,其中該藥物另外包含至少一種選自由紫杉醇(paclitaxel)、順鉑、5-氟尿嘧啶、長春瑞濱(vinorelbine)、西妥昔單抗(cetuximab)及其任何組合組成之群之藥劑或與其組合使用。
- 如請求項1之用途,其中該抗體係抗HER2抗體,其選自由曲妥珠單抗(trastuzumab)、西妥昔單抗及其任何抗原結合片段組成之群。
- 如請求項1至3中任一項之用途,其中該癌症係乳癌。
- 如請求項4之用途,其中該乳癌係選自以下組成之群: (i)HER1及/或HER2過度表現之雌激素受體陰性乳癌; (ii)雌激素受體-及孕酮受體-雙陽性乳癌,表現HER2但沒有過度表現; (iii)HER2過度表現之曲妥珠單抗耐藥性乳癌;及 (iv) PR、HER2及雌激素受體陰性的HER1過度表現之乳癌。
- 如請求項5之用途,其中該乳癌係轉移性乳癌。
- 如請求項6之用途,其中該治療另外包括以下初步步驟: 自該個體收集乳癌細胞;及 評估該乳癌細胞以確認HER2之過度表現,或 HER2之突變體之過度表現,或HER2基因之擴增,或 HER2基因之突變體之擴增。
- 如請求項7之用途,其中該評估步驟包括免疫組織化學(IHC)及確認螢光原位雜交(FISH)。
- 如請求項8之用途,其中該IHC係IHC 3+或IHC 2+。
- 一種波齊替尼製備用於治療有此需要之個體乳癌之藥物之用途,其中該乳癌係與HER2之過度表現或擴增、或HER2之突變體之過度表現或擴增相關,該治療包括以下步驟: a)在21天週期±3天中: i)投與單一劑量之T-DM1,範圍為1.5-5.5 mg/kg; ii)以0.5-50 mg/天之波齊替尼每日劑量投與該藥物;及 iii)視需要在該21天週期內休止治療一段時間; 及 b)視需要重複該週期或該週期之變型。
- 如請求項10之用途,其中該21天週期包括2週之藥物投與及1週休止期。
- 如請求項11之用途,其中該21天週期係選自由以下組成之群: 投藥兩週,接著休止一週; 投藥一週,接著休止一週,接著再投藥一週;及 休止一週,接著投藥兩週。
- 如請求項10之用途,其中T-DM1係藉由靜脈內(IV)輸注投與。
- 如請求項13之用途,其中該T-DM1標準劑量為3.6 mg/kg。
- 如請求項10至14中任一項之用途,其中該波齊替尼藥物係口服投與。
- 如請求項15之用途,其中該口服劑量係選自由每天一次6、8、10、12、16及24 mg組成之群。
- 一種波齊替尼之用途,其用於製備用於改善經歷與HER2或HER2突變體之過度表現或擴增相關乳癌治療之個體不良事件概況之藥物,其中該治療包括以下步驟: a)在21天週期±3天中: i)投與單一劑量之T-DM1;及 ii)投與每日劑量之波齊替尼藥物; 及 b)視需要重複該週期, 其中該不良效應係選自由心臟毒性、血液學毒性、腹瀉、皮疹、黏膜炎、疲勞、電解質異常及肝毒性組成之群。
- 一種用於治療個體之乳癌之組合,其中該乳癌係與HER1、HER2或HER4,或HER1、HER2或HER4之突變體之過度表現或擴增相關,該組合包含治療有效量之波齊替尼及T-DM1,其中波齊替尼係口服投與及T-DM1係由IV輸注投與。
- 如請求項18之組合,其另外包含藉由靜脈內(IV)輸注投與之治療有效量之紫杉醇。
- 一種波齊替尼製備用於治療個體之胃癌之藥物之用途,其中該藥物包含抗HER1、抗HER2或抗HER4抗體或與其組合使用, 其中該胃癌係與HER1、HER2或HER4,或HER1,HER2或HER4之突變體之過度表現或擴增相關。
- 如請求項21之用途,其中該藥物另外包含至少一種選自紫杉醇、順鉑、5-氟尿嘧啶、長春瑞濱、西妥昔單抗及其任何組合組成之群之藥劑或與其組合使用。
- 如請求項20之用途,其中該抗體係抗HER2抗體,其選自由曲妥珠單抗、西妥昔單抗及其任何抗原結合片段組成之群。
- 如請求項20之用途,其中該治療另外包括以下初步步驟: 自該個體收集胃癌細胞;及 評估該等胃癌細胞以確認HER2之過度表現,或 HER2之突變體之過度表現,或HER2基因之擴增,或 HER2基因之突變體之擴增。
- 如請求項23之用途,其中該評估步驟包括免疫組織化學(IHC)及確認螢光原位雜交(FISH)。
- 如請求項24之用途,其中該IHC係IHC 3+或IHC 2+。
- 如請求項20至25中任一項之用途,其中該胃癌先前已經用化療方案治療。
- 一種波齊替尼製備用於治療有需要之個體胃癌之藥物之用途,其中該胃癌係與HER2之過度表現或擴增,或HER2之突變體之過度表現或擴增相關,其中該治療包括以下步驟: a)在21天週期±3天中: i)投與單一劑量之曲妥珠單抗,範圍為6-8 mg/kg; ii)投與單一劑量之紫杉醇,範圍為105-175 mg/m2 ;及 iii)投與每日劑量之波齊替尼藥物,範圍為4-16 mg/天; 及 b)視需要重複該週期。
- 如請求項27之用途,其中曲妥珠單抗係在第1天藉由靜脈內(IV)輸注投與。
- 如請求項27之用途,其中該曲妥珠單抗標準劑量係8 mg/kg速效(loading),接著6 mg/kg輸注。
- 如請求項27之用途,其中該紫杉醇係在第1天藉由靜脈內(IV)輸注投與。
- 如請求項30之用途,其中該紫杉醇標準劑量係175 mg/m2 輸注。
- 如請求項27至31中任一項之用途,其中該波齊替尼藥物係口服投與14±3天。
- 如請求項32之用途,其中該口服劑量係選自每天一次4、6、8、10、12及16 mg。
- 如請求項33之用途,其中7天的休止期跟在14天波齊替尼投與之後。
- 一種波齊替尼之用途,其用於製備用於改善經歷與HER2或HER2之突變體之過度表現或擴增相關之胃癌治療之個體中不良事件概況之藥物,其中該治療包括以下步驟: a)在21天週期±3天中: i)投與單一劑量之T-DM1;及 ii)投與每日劑量之波齊替尼藥物; 及 b)視需要重複該週期, 其中該不良效應係選自由心臟毒性、血液學毒性、腹瀉、皮疹、黏膜炎、疲勞、電解質異常及肝毒性組成之群。
- 一種用於治療個體之胃癌之組合,其中該胃癌係與HER1、HER2或HER4,或HER1、HER2或HER4之突變體之過度表現或擴增相關,該組合包含治療有效量之波齊替尼及T-DM1,其中波齊替尼係口服投與及T-DM1係由IV輸注投與。
- 如請求項36之組合,其另外包含藉由靜脈內(IV)輸注投與之治療有效量之紫杉醇。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862689282P | 2018-06-25 | 2018-06-25 | |
US62/689,282 | 2018-06-25 | ||
US201962812656P | 2019-03-01 | 2019-03-01 | |
US62/812,656 | 2019-03-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW202005651A true TW202005651A (zh) | 2020-02-01 |
Family
ID=68986030
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW108122227A TW202005651A (zh) | 2018-06-25 | 2019-06-25 | 波齊替尼(poziotinib)與抗her1、her2或her4抗體之組合及使用彼之方法 |
Country Status (14)
Country | Link |
---|---|
US (1) | US20210260064A1 (zh) |
EP (1) | EP3810130A4 (zh) |
JP (1) | JP2021529179A (zh) |
KR (1) | KR20210025064A (zh) |
CN (1) | CN112423745A (zh) |
AU (1) | AU2019292186A1 (zh) |
BR (1) | BR112020026382A2 (zh) |
CA (1) | CA3098204A1 (zh) |
IL (1) | IL279325A (zh) |
MX (1) | MX2020014104A (zh) |
PH (1) | PH12020552159A1 (zh) |
SG (1) | SG11202012067YA (zh) |
TW (1) | TW202005651A (zh) |
WO (1) | WO2020005934A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3897650A4 (en) * | 2018-12-21 | 2022-12-28 | Board of Regents, The University of Texas System | POLYTHERAPY FOR THE TREATMENT OF CANCER |
WO2021191094A1 (en) * | 2020-03-24 | 2021-09-30 | University Court Of The University Of Edinburgh | Erbb-targeted therapies for neuropathic pain |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8828391B2 (en) * | 2011-05-17 | 2014-09-09 | Boehringer Ingelheim International Gmbh | Method for EGFR directed combination treatment of non-small cell lung cancer |
EP2947460A1 (en) * | 2014-05-22 | 2015-11-25 | Medizinische Universität Wien | Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists |
KR102585006B1 (ko) * | 2016-11-17 | 2023-10-05 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Egfr 또는 her2 엑손 20 돌연변이를 갖는 암 세포에 대한 항종양 활성을 갖는 화합물 |
-
2019
- 2019-06-25 CN CN201980029655.2A patent/CN112423745A/zh active Pending
- 2019-06-25 JP JP2020571811A patent/JP2021529179A/ja active Pending
- 2019-06-25 TW TW108122227A patent/TW202005651A/zh unknown
- 2019-06-25 SG SG11202012067YA patent/SG11202012067YA/en unknown
- 2019-06-25 US US17/250,259 patent/US20210260064A1/en active Pending
- 2019-06-25 KR KR1020217001979A patent/KR20210025064A/ko unknown
- 2019-06-25 MX MX2020014104A patent/MX2020014104A/es unknown
- 2019-06-25 EP EP19826967.2A patent/EP3810130A4/en not_active Withdrawn
- 2019-06-25 AU AU2019292186A patent/AU2019292186A1/en not_active Abandoned
- 2019-06-25 WO PCT/US2019/038974 patent/WO2020005934A1/en unknown
- 2019-06-25 CA CA3098204A patent/CA3098204A1/en active Pending
- 2019-06-25 BR BR112020026382-6A patent/BR112020026382A2/pt not_active Application Discontinuation
-
2020
- 2020-12-09 IL IL279325A patent/IL279325A/en unknown
- 2020-12-11 PH PH12020552159A patent/PH12020552159A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20210260064A1 (en) | 2021-08-26 |
PH12020552159A1 (en) | 2021-07-05 |
SG11202012067YA (en) | 2021-01-28 |
WO2020005934A8 (en) | 2020-07-16 |
EP3810130A1 (en) | 2021-04-28 |
IL279325A (en) | 2021-01-31 |
MX2020014104A (es) | 2021-05-27 |
KR20210025064A (ko) | 2021-03-08 |
JP2021529179A (ja) | 2021-10-28 |
EP3810130A4 (en) | 2022-03-09 |
CA3098204A1 (en) | 2020-01-02 |
WO2020005934A1 (en) | 2020-01-02 |
AU2019292186A1 (en) | 2020-12-17 |
CN112423745A (zh) | 2021-02-26 |
BR112020026382A2 (pt) | 2021-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2736005T3 (es) | Pertuzumab, Trastuzumab, Docetaxel y Carboplatino para el tratamiento del cáncer de mama en fase precoz | |
US20150231238A1 (en) | Overcoming resistance to erbb pathway inhibitors | |
ES2535404T5 (es) | Uso de anticuerpo anti-VEGF en combinación con quimioterapia para tratar cáncer de mama | |
JP2020172487A (ja) | トラスツズマブ−mcc−dm1及びペルツズマブにより早期の乳癌を処置する方法 | |
WO2013138371A1 (en) | Methods for treating pancreatic cancer using combination therapies comprising an anti-erbb3 antibody | |
TW200838875A (en) | Combination therapy with angiogenesis inhibitors | |
TW201922793A (zh) | Pd-1抗體和vegfr抑制劑聯合治療小細胞肺癌的用途 | |
Schinzari et al. | Targeted therapy in advanced gastric carcinoma: the future is beginning | |
KR20210041571A (ko) | 역형성 림프종 키나아제 억제제와 조합하여 egf/egfr 경로를 억제하기 위한 방법 및 조성물 | |
WO2020249018A1 (zh) | 治疗驱动基因阳性肺癌的联用药物组合物 | |
TW202005651A (zh) | 波齊替尼(poziotinib)與抗her1、her2或her4抗體之組合及使用彼之方法 | |
JP2022027658A (ja) | チロシンキナーゼ阻害剤と併用してegf/egfr経路を抑制する方法および組成物 | |
AU2018389196A1 (en) | Methods and combination therapy to treat cancer | |
Murphy et al. | State of the art management of metastatic gastroesophageal cancer | |
TW202019412A (zh) | 波齊替尼(poziotinib)與細胞毒性劑及/或其他分子靶向劑之組合及其用途 | |
US20230321087A1 (en) | Fgfr inhibitor combination therapies | |
Dong et al. | Phase 1 Study of the Selective c-MET Inhibitor, HS-10241, in Patients With Advanced Solid Tumors | |
KR20200105825A (ko) | 삼중 음성 유방암의 치료를 위한 pd-1 항체 및 아파티닙의 조합 치료의 용도 | |
Lee et al. | Changing Paradigms in the Treatment of Advanced Urothelial Carcinoma: A 2020 Update | |
US20190211102A1 (en) | Methods and combination therapy to treat cancer | |
CN117120074A (zh) | sEphB4-HSA融合蛋白作为癌症治疗的一线疗法的用途 | |
WO2022031568A1 (en) | Treatment of cll | |
WO2021088853A1 (zh) | 喹啉衍生物与pd-1单抗的药物组合 | |
CN114470191A (zh) | 喹啉衍生物与pd-1单抗的药物组合 | |
TW201011046A (en) | Inhibitors of the epidermal growth factor receptor (EGFR) with cytostatic effect and their uses in tumor therapy |